Blood Thinner Xarelto
Xarelto (rivaroxaban) is a drug that was approved by the U.S. Food and Drug Administration (FDA) in July 2011. Xarelto was touted as an improvement over warfarin, an anticoagulant that has been in use for several decades. Unfortunately, since then, the FDA has received a large number of ‘adverse event reports’. This means that in 2012, over 750 serious injuries and deaths were reported. There have likely been many thousands more since.
It is true that any drug can have adverse side effects. There are two major problems with Xarelto, however. First, and most alarming, is that people taking Xarelto may have uncontrollable bleeding. While this is a risk shared by all blood thinners, there is currently no antidote in the event of a serious incident. Warfarin bleeding, by contrast, can be staunched rather quickly via the administration of vitamin K. There are many who believe that Xarelto should not have been released with this important safety measure in place.
Secondly, this problem has been compounded by the marketing of Xarelto. Anyone on a blood thinning agent should have routine monitoring. Because this is unpleasant for patients, the manufacturers of Xarelto have seized upon that and made the ‘NO monitoring’ claim as their #1 selling point.
Some doctors have begun to be concerned about Xarelto. Some patients have had major bleeding incidents. Bayer and Johnson & Johnson are now facing lawsuits. Court documents indicate that these claims accuse the companies of withholding information from consumers and the medical community regarding a lack of an agent to reverse uncontrollable internal bleeding. The plaintiffs in these cases also assert that the benefits associated with Xarelto do not justify its risks.
This website will provide regular medical and legal information regarding Xarelto.